CUAJ, Editor. 2026. “Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients With Urological Cancers – Adverse Events (AEs): Management Tool Kit”. Canadian Urological Association Journal 15 (1X). https://cuaj.ca/index.php/journal/article/view/9883.